Abstract
Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents. However, adjudicating criteria on whether improvements are a glycemic or nonglycemic effect of these agents remain unclear. Hypoglycemic agents that produce a cardiovascular benefit in nondiabetic patients are considered to do so via a nonglycemic effect. We performed a subgroup analysis for primary and secondary prevention or very high risk of ASCVD in patients with type 2 diabetes (T2DM). Where glycosylated hemoglobin (HbA1c) was reduced to the same extent in a head-to-head comparison, cardiovascular benefits were judged as a nonglycemic effect. Furthermore, by analyzing the endpoints of four important randomized controlled intensive glucose control studies, UKPDS33, ADVANCE, ACCORD, and VADT, we calculated the cut point of HbA1c reduction for a nonglycemic effect on cardiovascular benefit by hypoglycemic agents in ASCVD groups of different severities. For the ASCVD primary prevention group of T2DM, UKPDS33 indicated a reduction in HbA1c < 0.9%, and a cardiovascular benefit within 10 years was considered a nonglycemic effect. For ASCVD secondary prevention or in the very hig...Continue Reading
References
Jul 24, 2003·JAMA : the Journal of the American Medical Association·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trial Research Group
Mar 29, 2005·Diabetes Care·Robert RatnerUNKNOWN Diabetes Prevention Program Research Group
Oct 11, 2005·Lancet·John A DormandyUNKNOWN PROactive Investigators
May 7, 2008·Diabetes Care·Ajay D RaoVivian A Fonseca
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Sep 17, 2009·Current Pharmaceutical Design·N Papanas, E Maltezos
Mar 23, 2011·Acta Diabetologica·Evren FidanCihangir Erem
Jul 28, 2011·BMJ : British Medical Journal·Rémy BoussageonCatherine Cornu
Dec 12, 2012·Diabetes Care·Jie HongUNKNOWN SPREAD-DIMCAD Investigators
Jul 31, 2013·American Heart Journal·Bruce NealDavid Matthews
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Feb 19, 2014·Diabetes, Obesity & Metabolism·S E Holden, C J Currie
Feb 26, 2015·Diabetes, Obesity & Metabolism·A S AbdelmoneimS H Simpson
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Feb 18, 2016·The New England Journal of Medicine·Walter N KernanUNKNOWN IRIS Trial Investigators
Mar 21, 2016·American Heart Journal·Rury R HolmanAdrian F Hernandez
Mar 28, 2016·International Journal of Cardiology·Raktim Kumar GhoshAnjan Gupta
May 22, 2016·Diabetes Care·Robert J SmithWilliam R Hiatt
Jun 12, 2016·Diabetes Care·Ele FerranniniEric Mayoux
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Aug 16, 2016·Cardiovascular Diabetology·Angelo AvogaroStefano Del Prato
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Sep 17, 2016·Current Vascular Pharmacology·Vasilios G AthyrosNikolaos Tentolouris